Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.76 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | PI4KA | P42356 | 1/20 | 0.46 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.46 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12498653 | 0.85 | CYP1A2 (0.78) | CYP1A2CYP2D6MAPK1ADORA2AADORA1 | |
| SCHEMBL27943333 | 0.83 | CYP1A2 (0.76) | CYP1A2CYP2D6MAPK1ADORA2AADORA1 | |
| Hydrochloric Acid SCHEMBL8466597 | 0.81 | CYP1A2 (0.71) | CYP1A2CYP2D6MAPK1ADORA2AADORA1 | |
| SCHEMBL24236919 | 0.81 | CYP1A2 (0.71) | CYP1A2CYP2D6MAPK1ADORA2AADORA1 | |
| SCHEMBL5015543 | 0.81 | CYP1A2 (0.82) | CYP1A2CYP2D6MAPK1ADORA2AADORA1 | |
| SCHEMBL14924510 | 0.81 | CYP1A2 (0.82) | CYP1A2CYP2D6MAPK1ADORA2AADORA1 | |
| SCHEMBL934365 | 0.80 | CYP1A2 (0.69) | CYP1A2CYP2D6MAPK1ADORA2ASMN1; SMN2 | |
| SCHEMBL8464098 | 0.77 | CYP1A2 (0.75) | CYP1A2CYP2D6MAPK1ADORA2AADORA1 | |
| SCHEMBL14203129 | 0.77 | CYP1A2 (0.75) | CYP1A2CYP2D6MAPK1ADORA2AADORA1 | |
| SCHEMBL12941024 | 0.76 | CYP1A2 (0.64) | CYP1A2CYP2D6MAPK1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-20220033435-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | MERCK SHARP & DOHME CORP. (US) | 2022-02-03 | — | — | US | disclosed |
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | CYP1A2 1485/4885CYP2D6 2541/4885MAPK1 1162/4885 |
| US-20220033435-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | STING1, CGAS, IFNAR1 | CYP1A2 1793/4885CYP2D6 2780/4885MAPK1 1145/4885 |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | CYP1A2 1764/4885CYP2D6 3015/4885MAPK1 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.